

Periods	Prior to L-NMMA infusion period	At the end of L-NMMA infusion period	1 hour after L-NMMA infusion period	P (GLM-within)
PRC(pg/ml)				
Placebo	5.8± 1.6	4.4± 1.5	4.1± 1.7	0.633
Tolvaptan 15 mg	6.1± 2.1	4.2± 2.1	4.7± 2.0	
Tolvaptan 30 mg	6.3± 1.8	4.4± 1.7	4.5± 1.9	
Tolvaptan 45 mg	6.8± 1.8	4.9± 1.6	5.5± 1.5	
p (GLM between)		0.838		
P-AngII (pg/ml)				
Placebo	16.4± 2.3	13.5± 3.0	13.5± 2.9	0.864
Tolvaptan 15 mg	16.4± 2.6	12.2± 3.6	13.5± 3.3	
Tolvaptan 30 mg	13.5± 2.6	11.0± 1.8	11.0± 3.4	
Tolvaptan 45 mg	18.2± 2.2	14.9 ± 2.6	14.9± 2.7	
p (GLM between)		0.854		
P- Aldo (pmol/L)				
Placebo	69± 2	65 ± 2	59± 2	0.568
Tolvaptan 15 mg	67± 2	64± 2	67± 2	
Tolvaptan 30 mg	62± 2	63± 2	62± 2	
Tolvaptan 45 mg	69± 2	69± 2	69± 2	
p (GLM between)		0.999		